We report here the results of the GRAAPH-2003 trial with long-term follow-up in 45 patients with de novo Philadelphia chromosome-positive (Phþ) acute lymphoblastic leukemia (ALL). Imatinib-based strategy improved the 4-year overall survival (OS) up to 52% versus 20% in the pre-imatinib LALA-94 trial (P ¼ .0001). Despite the selection in patients who actually underwent transplantation, these results suggest that allogeneic or autologous stem cell transplants (SCTs) still have a place in overcoming the poor prognosis of Phþ ALL in the era of imatinib therapy. OS was 50% after allogeneic SCT (24 patients), 33% in patients without a transplantation (9 patients), and 80% after autologous SCT (10 patients without allogeneic donor or >55 years, including 7 patients in complete molecular response). Ó
INTRODUCTION
Philadelphia chromosome positive (Phþ) is the most frequent recurrent cytogenetic abnormality observed in adult patients diagnosed with acute lymphoblastic leukemia (ALL). Before the tyrosine kinase inhibitor (TKI) era, the outcome of patients with Phþ ALL was very poor, with longterm survival rates, at best, reaching 20% in most studies [1, 2] . Allogeneic stem cell transplant (SCT) has been considered as the consolidation treatment of choice once achieving a first complete remission (CR), as it provides the best outcome in this setting [3] . In recent years, the most significant advance in term of treatment has been the introduction of TKIs into Phþ ALL treatment protocols. Several groups have shown that the combination of concurrent or alternating use of imatinib with high-dose chemotherapy has significantly improved the outcome of adults and children with newly diagnosed Phþ ALL, with higher CR rates (nearly 95%) and 12-month overall survival (OS) reaching approximately 75% [4] [5] [6] [7] [8] [9] . However, to date, there is no evidence that TKIs may impact on the long-term outcome of patients with Phþ ALL, because the follow-up of published studies did not exceed 2 years [4] [5] [6] [7] [8] [9] [10] . In a first analysis of the GRAAPH-2003 study, CR rate, 18-month disease-free survival (DFS), and OS were 96%, 51%, and 65%, respectively [11] . In the present analysis, results of the GRAAPH-2003 study have been actualized with a longer median follow-up reaching 3.86 years.
PATIENTS AND METHODS
From January 2004 to October 2005, 45 patients with newly diagnosed de novo Phþ ALL (median age, 45 years; range, 16-59 years) were included in the GRAAPH-2003 study. The Phþ was detected by standard karyotype and/or fluorescence in situ hybridization analysis and/or BCR-ABL fusion transcript detection by reverse transcription-PCR. Patients with previous chronic myeloid leukemia or myeloproliferative disorders were excluded. All patients gave their written informed consent before the study. The study was approved in March 2003 by the institutional review board of Hôpital Purpan, Toulouse, France, and conducted in accordance with the Declaration of Helsinki. Details regarding this study have been published elsewhere [11] .
The protocol schedule is summarized in Figure 1 . Following a 7-day prednisone pre-phase, corticosteroid sensitivity (CS) was assessed by peripheral blood examination and was defined as <1.0 Â 10 9 /L residual circulating blasts. Chemotherapy sensitivity (ChS) was assessed by peripheral blood and bone marrow (BM) examination 8 days after the start of an induction chemotherapy including daunorubicin, cyclophosphamide,
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Patients with a BM MRD ratio <10
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, but without any donor or >55 years, were eligible for autologous SCT. Patients who failed to achieve this BM MRD level were further treated with imatinib combined with various chemotherapy regimens.
Results of the GRAAPH-2003 study were compared to those obtained by the pre-imatinib French trial, LALA-94 [2] , which included 154 patients with de novo Phþ ALL between 1994 and 2000, and used standard induction chemotherapy combining prednisone, vincristine, and cyclophosphamide with an anthracycline (daunorubicin or idarubicin) followed by a consolidation course combining mitoxantrone with intermediate-dose cytarabine (HAM). All of the 103 patients in hematological CR after these 2 chemotherapy courses underwent allogeneic SCT if a matched donor was identified, or autologous SCT if not.
Statistical Analysis
An update of the database was performed by May 18, 2012. At this time point, the median follow-up was 2.46 years for the overall group of patients (range, 0.05-4.98 years) and 3.86 years for those alive at the last follow-up evaluation (range, 0.9-4.98 years). All analyses were conducted according to the intention-to-treat principle. DFS was measured from the time of first CR to the date of relapse or death, whatever the cause. Relapse was defined as leukemia recurrence after first CR. OS was defined as the time interval from randomization until death, whatever the cause. The probabilities of DFS and OS were estimated according to the Kaplan-Meier product limit method and compared using either the 2-tailed log-rank test or Cox proportional hazards regression analysis. Departure from the proportional hazards assumption was assessed using methods based on partial residuals and a graphical approach. Competing risks analysis and the Gray test were used to calculate and compare the cumulative incidence of treatmentrelated death and relapse between groups. The Fine and Gray model was used to estimate relative risks (RRs) and 95% confidence intervals (CIs) for competing risks analyses. According to group size, chi-square analysis or Fisher exact test was used to compare categorical covariates. The MannWhitney U test was used to compare medians. All statistical analyses were conducted with S-Plus 8.0 for Windows Enterprise Developer (Insightful Corporation, Seattle, WA).
RESULTS
As previously reported [11] , the CR rate after the induction phase was 96%. First CR was achieved in 14 patients (31%) after mitoxantrone, intermediate dose cytarabine, and imatinib, and 29 patients (64%) after DIV ( Figure 1 ). Two patients died during DIV chemotherapy. Twenty-four of the 43 patients in CR received allogeneic SCT from either an HLAidentical sibling donor (n ¼ 15) or an HLA-matched unrelated donor (n ¼ 8), or from an unrelated cord blood donor (n ¼ 1).
Nineteen patients in CR did not receive allogeneic SCT because they were >55 years (n ¼ 4) or had no available or identified donor (n ¼ 15). Among them, 10 received intensification therapy followed by autologous SCT. Seven patients achieved at least a low MRD level before undergoing the transplantation procedure, whereas 3 patients had positive pretransplantation MRD. Although no maintenance therapy was planned after SCT, 4 of these 10 patients received imatinib. Furthermore, 9 patients received an "off protocol" maintenance chemotherapy with imatinib because they failed to achieve a low MRD level (n ¼ 4) or because investigators waited for the identification of an HLA-matched unrelated donor before to resolve to perform autologous SCT (Table 1) . For the entire cohort, the 4-year OS and DFS were 52% (95% CI, 39%-70%) and 44% (95% CI, 31%-62%), respectively ( Figure S1A and B, online only). A highly significant improvement of the outcome was observed when compared to the LALA-94 trial ( Table 2 ). The 4-year cumulative incidence rates of relapse and treatment-related mortality (TRM) were 36% (95% CI, 21%-51%) and 21% (95% CI, 8%-34%), respectively. In univariate analysis, WBC count at the time of diagnosis was the only covariate affecting significantly relapse incidence and DFS ( Figure S1C and D, online only) (when considering the logarithm of the WBC count at diagnosis, i.e., leukocytosis as a continuous covariate: RR for the 4-year DFS, 1.45; 95% CI, 1.03-2.05; P ¼ .034; RR for the 4-year relapse incidence, 1.61; 95% CI, 1.06-2.45; P ¼ .027). Table 3 summarizes the 43 remitters, the 4-year cumulative incidence of relapse, the 4-year TRM rate, the 4-year OS, and the 4-year DFS ( Figure S2A and B, online only) according to the type of consolidation treatment (allogeneic SCT versus autologous SCT versus chemotherapy alone). The only significant difference was observed in terms of OS between patients who received autologous SCT and those who did not undergo transplantation.
Regarding the outcome of the 24 patients who received allogeneic SCT, a significant difference was observed according to the type of donor (HLA-identical sibling versus unrelated donor) in terms of OS, DFS, and TRM (Table 3 - Figure 2) . The best results were observed in patients who underwent transplantation from an HLA-identical sibling donor, whereas those who underwent transplantation from an unrelated donor presented a higher TRM rate (1-year TRM, 22%; 95% CI, 0%-51% versus 7%; 95% CI, 0%-20%), without any gain in terms of relapse incidence. Patients undergoing autologous SCT had a similar 4-year OS than those receiving allogeneic SCT from an HLA-identical sibling donor. The higher relapse incidence observed in patients who received autologous SCT was balanced by a lower TRM rate. Table 3 also shows outcome according to the MRD level achieved after the induction phase. There were no statistically significant differences in terms of survival between patients with high, low, or negative MRD levels after the induction phase ( Figure S3 , online only). Similar results were observed when considering the MRD level as a continuous variable. For the entire cohort, relapse incidence decreased concomitantly to MRD level ( Figure 3) . TRM was inversely correlated to the relapse incidence, and higher TRM rates were correlated to negative MRD levels ( Figure 3 ). Similar results were observed when only considering patients who received allogeneic SCT (data not shown).
DISCUSSION
This updated analysis of the GRAAPH-2003 trial confirms and extends the previously published results [11] . Results are in agreement with those from other reports suggesting that, in patients with Phþ ALL, the addition of imatinib to first-line chemotherapy is associated with an improved long-term outcome [12] [13] [14] .
Our results suggest that even when including imatinib during the induction phase, the prognosis of patients can again be improved by intensifying the postremission phase, through either autologous SCT (especially if a low or negative MRD level is achieved after the induction phase) or allogeneic SCT, especially from an HLA-identical sibling. In both "optimized situations," the 4-year OS was above 75% (4-year OS, 76%; 95% CI, 56%-100% with allogeneic SCT from an HLAidentical sibling (4-year OS, 86%; 95% CI, 63%-100% with autologous SCT and MRD low or negative), and the 4-year DFS above 70% (4-year DFS, 71%; 95% CI, 51%-100% with allogeneic SCT from an HLA-identical sibling (4-year DFS, 78%; 95% CI, 55%-100% with autologous SCT and MRD low or negative). Results of autologous SCT were encouraging with no TRM and a relapse incidence not statistically different from that observed after allogeneic SCT. These results might be explained by the fact that imatinib administration was stratified according to the MRD level assessed after the induction phase, in contrast with the methods of imatinib administration in previous studies [13, 14] . Therefore, most of the patients who underwent autologous SCT were good early responders. The 3 patients who received autologous SCT, despite a positive pretransplantation MRD evaluation, relapsed (at 1, 4, and 18 months posttransplantation, respectively). Although not planned in the protocol, 4 patients received imatinib as maintenance therapy after autologous SCT, which could have influenced the outcome of this group of patients. Among them, 3 patients were still alive in first CR at 37, 41, and 46 months posttransplantation, and 1 patient who has relapsed after 1 month remained alive at 48 months posttransplantation. Finally, although not statistically significant, lower WBC counts at diagnosis were observed in patients who received autologous SCT comparatively to those observed in patients who received an allogeneic SCT group from an HLA-identical sibling donor (median leukocytosis: 8 G/L versus 26 G/L, respectively). This covariate was the only one associated with 2 of the main endpoints for the entire cohort: the 4-year DFS and the relapse incidence. Only 1 patient with a WBC count above 50 G/L received autologous SCT. He rapidly relapsed despite the achievement of a low MRD level after the induction phase. Our results, although based on a limited number of patients, suggest that the autologous SCT option should be reconsidered in the imatinib era for Phþ ALL patients with a low or negative MRD level after the induction phase. In our previous LALA-94 trial [2] , we reported a favorable prognostic value when molecular remission was obtained after 2 chemotherapy courses independently of the presence of a donor. Molecular response was therefore considered as a good surrogate endpoint of the disease, and autologous SCT was avoided in patients with persistent MRD. The potential role of imatinib, as maintenance therapy after SCT in order to further reduce relapse incidence, remains an important issue that should be addressed prospectively. Radich et al. [15] , in a retrospective series of 36 patients with Phþ ALL who underwent transplantation at the Fred Hutchinson Cancer Research Center, and subsequently Stirewalt et al. [16] , analyzing the outcome of 90 patients with Phþ ALL who underwent transplantation at the same center, showed that the persistent expression of BCR-ABL during the first 100 days posttransplantation was associated with a higher incidence of relapse and a lower DFS. Both studies argue in favor of a maintenance therapy with imatinib after transplantation in patients with a positive MRD evaluation, especially when no chronic graft-versus-host immune reaction can be expected.
Unexpectedly, early MRD evaluation did not significantly influence patient outcome, both in terms of OS and DFS. The benefit of a low or negative MRD level, which translated into a significant lower incidence of relapse, was almost completely abrogated by the fact that these patients , 56%-100%) for those who received allogeneic stem cell transplant (SCT) from an HLA-identical sibling donor (black curve), 11% (95% CI, 2%-70%) for those who received allogeneic SCT from an unrelated donor (blue curve), 80% (95% CI, 59%-100%) for those who received autologous SCT (red curve), and 33% (95% CI, 11%-98%) for those who did not undergo transplantation (green curve) (P value [logrank test] < .0003). (B) The 4-year DFS was 71% (95% CI, 51%-100%) for those who received allogeneic SCT from an HLA-identical sibling donor (black curve), 11% (95% CI, 2%-70%) for those who received allogeneic SCT from an unrelated donor (blue curve), 50% (95% CI, 27%-93%) for those who received autologous SCT (red curve), and 33% (95% CI, 11%-98%) for those who did not undergo transplantation (green curve) (P value [log-rank test] ¼ .07). Figure 3 . Four-year relapse incidence and treatment-related mortality (TRM) of the 43 patients who achieved complete remission (CR) in the GRAAPH-2003 study according to the minimal residual disease (MRD) level after the induction phase. The 4-year relapse incidence was 8% (95% confidence interval [CI], 0%-23%) for those who had a negative MRD evaluation (red curve), 40% (95% CI, 14%-66%) for those who had a low MRD level evaluation (dark blue curve), and 71% (95% CI, 41%-100%) for those who had a high MRD level evaluation (black curve) (P value [Gray test] < .014). The 4-year TRM was 38% (95% CI, 10-66%) for those who had a negative MRD evaluation (light blue curve), 13% (95% CI, 0-31%) for those who had a low MRD level evaluation (orange curve), and 0% for those who had a high MRD level evaluation (green curve) (P value [Gray test] ¼ .038).
experienced the highest TRM rate. This was observed mainly for patients who received allogeneic SCT, and especially for those who underwent transplantation with an unrelated donor. In this group, a particularly poor outcome was observed with a 4-year TRM greater than 40% and a 4-year OS and DFS of only 11%. Combined with the relatively advanced age of patients with Phþ ALL and the high probability of graft-versus-leukemia effect in this disease [17] , these results tend to argue in favor of allogeneic SCT after reduced-intensity conditioning for adult patients with Phþ ALL when no HLA-identical sibling donor is available. Whether autologous SCT with a low or negative MRD level should be performed instead of allogeneic SCT using an HLAmatched unrelated donor in patients with Phþ ALL is a critical issue that should further be addressed through a prospective controlled study.
